SUB-INDUSTRY Cell/Gene Therapy
Genenta Science S.p.A. is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™.
– Genenta was seeking new capital to advance clinical trials in order to:
– carry out phase 2 clinical trials of the Temferon product in Italy
– fund Temferon manufacturing activities for the phase 2 study
– finanziare le attività di produzione di Temferon per lo studio della fase 2
THE ADVISOR’S SUPPORT
Growth Capital has advised Genenta’s management team.
Connecting outstanding entrepreneurs and visionary investors